South Africa: TAC, COSATU and allies file complaint of excessive pricing.
On 19 September 2002, the Treatment Action Campaign (TAC), the Council of South African Trade Unions (COSATU), the Chemical, Energy, Paper, Printing, Wood and Allied Workers' Union (CEPPWA), and eight individuals (health-care workers and people living with HIV/AIDS) launched a complaint with the country's Competition Commission against two major transnational pharmaceutical companies. TAC and its allies allege that GlaxoSmithKline (GSK) has engaged in excessive pricing for its antiretroviral drugs Retrovir (zidovudine or AZT), 3TC (lamivudine), and Combivir (AZT/lamivudine), and that Boeringer Ingelheim (BI) has engaged in excessive pricing of its antiretroviral drug Viramune (nevirapine).
Elliott
Richard
R
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000191:economics*; D003365:Costs and Cost Analysis / Q000331:legislation & jurisprudence*; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D004359:Drug Therapy, Combination; D016568:Drugs, Generic; D004465:Economic Competition; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D013019:South Africa
D019380:Anti-HIV Agents; D016568:Drugs, Generic